[OT] Leiden, the Netherlands, is home to some innovative companies. In addition to Octoplus, companies headquartered in Leiden include Crucell and Pharming (the company whose business model is most similar to that of GTCB).
Interesting. For those that aren't aware, SRDX has a relationship with Octoplus on the application of biodegradable polymers for use in drug-eluting medical device applications.
OctoPlus announces plans for listing on Euronext Amsterdam
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
OctoPlus, the drug delivery and development company, announces that it is planning to raise, within the next few months, new funds through an initial public offering (IPO) on the Euronext Amsterdam stock exchange. Cowen and Company and Fortis Bank have been appointed as joint bookrunners and joint global co-ordinators, and Kempen and Co has been appointed as co-manager.
OctoPlus is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products, based on its proprietary drug delivery technologies. OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. OctoPlus is located in Leiden, the Netherlands. The company was founded in 1995 and currently employs some 130 people.
This announcement is not an offer to sell or the solicitation of any offer to buy securities of OctoPlus (the “Securities”) in the United States or in any other jurisdiction. The Securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States unless registered under the Securities Act or an exemption from such registration is available.
Any offer to acquire Securities pursuant to the proposed offering will be made, and any investor should make his investment, solely on the basis of information that will be contained in the prospectus to be made generally available in the Netherlands in connection with such offering. When made generally available, copies of the prospectus may be obtained at no cost from OctoPlus, Fortis Bank N.V. or Kempen and Co. or through the website of OctoPlus and Euronext Amsterdam (Dutch residents only)."
Market Data 
Markets 
AI
